What Is Meant by Overcoming Resistance to Targeted Therapies in NSCLC?
Resistance occurs when NSCLC cells stop responding to treatments that were initially effective. This can happen when cancer cells change their DNA or find new ways to thrive. Doctors try to overcome this resistance by using newer medications, combining treatments, or employing sophisticated therapeutics such as antibody-drug conjugates. Tests like liquid biopsy can also help find resistance early on and help doctors choose the best treatment.
Why Do NSCLC Patients Develop Resistance to Targeted Therapies?
Resistance to targeted drugs arises when cancer cells that initially respond to treatment gradually stop responding. This reduces the treatment's long-term efficacy. It is divided into two types: primary and secondary resistance.
1. Primary Resistance
-
Primary resistance develops when cancer cells do not respond to targeted therapy at the start of treatment. This occurs because the tumor already contains genetic alterations that prevent the medicine from working. It can also arise from tumor heterogeneity, in which multiple cancer cell types coexist within a single tumor.
-
Certain mutations, including EGFR exon 20 insertions, are inherently resistant to EGFR inhibitors in EGFR-targeted therapy. The efficacy of the medication may be diminished in a small percentage of cases where the EGFR T790M mutation is already present. Intrinsic resistance may arise via MET gene amplification.
-
Drugs such as Crizotinib are routinely used in ALK-targeted therapy, but some cancers do not respond well to it initially. This could be due to differing versions of the EML4-ALK fusion gene, which influence how the medication interacts with cancer cells.
2. Secondary (Acquired) Resistance
Secondary resistance emerges following an initial positive response to targeted therapy. Cancer cells adapt and accumulate new mutations over time, allowing them to thrive even when exposed to treatment.
-
The T790M mutation is one of the most common mechanisms of resistance to EGFR-targeted therapy. It is found in almost half of those patients. Genetic changes, such as mutations in PIK3CA or BRAF, may activate new signaling pathways. This helps the cancer cells to proliferate. The cancer cells may avoid the drug by following a different route. The cancer may follow a different growth pathway when the first is blocked. A usual way for NSCLC to resist is through bypass signaling.
-
Sometimes, the tumor may change from non-small cell lung cancer to small cell lung cancer or go through an epithelial-to-mesenchymal transition, which means that treatment won't work anymore.
-
Acquired resistance can occur through both ALK-dominant and ALK-non-dominant pathways in ALK-targeted therapy. Because of more changes in the EML4-ALK fusion protein, treatments like crizotinib can't bind to ALK-dominant resistance very well. Other cancer pathways are turned on when ALK is not dominant. This accelerates tumor growth via multiple signaling pathways.
-
These resistance mechanisms hamper lung cancer treatment, emphasizing the need for more effective drugs and novel treatment approaches.
What Are the Treatment Approaches to Overcome Resistance In Targeted Therapy Resistance in NSCLC?
1. Next Generation Drugs
-
Researchers are developing new targeted medicines called tyrosine kinase inhibitors (TKIs) to address resistance that can develop during cancer treatment. These drugs are designed to remain effective even when cancer cells develop new mutations that make earlier treatments stop working.
-
Recent inhibitors are made to target cancer cells that have become resistant while causing less harm to healthy cells. Some people may respond better to treatment with this more targeted approach. Osimertinib and Rociletinib are examples of third-generation EGFR inhibitors designed to address resistance that may arise with earlier EGFR-targeted therapies. These medications can target particular resistant alterations that may arise following initial treatment, such as the T790M mutation.
-
When resistance to the ALK inhibitor Crizotinib develops, doctors may adjust the treatment plan. If the cancer has spread to areas such as the brain, the same drug may sometimes be continued while local treatments like radiation are used to control the tumour. If the disease progresses further, treatment is usually switched to a newer ALK-targeted therapy.
-
Second-generation ALK inhibitors, including Ceritinib and Alectinib, have shown encouraging results in patients whose cancer no longer responds to Crizotinib. These medicines may be used in both newly diagnosed ALK-positive lung cancer and in patients previously treated with Crizotinib. Alectinib has also shown strong activity against cancer that has spread to the brain.
-
Researchers are also studying other newer ALK inhibitors, such as Brigatinib, Entrectinib, TSR-011, and CEP-37440. These drugs are being explored for their ability to target specific ALK mutations and may offer additional treatment options for people with resistant non-small cell lung cancer (NSCLC).
2. Combination Therapy
-
Combination therapies can increase the effectiveness of targeted therapy. This method employs targeted medications along with other therapies, such as chemotherapy or additional targeted agents. Patients with EGFR-mutant malignancies, for example, could be given EGFR tyrosine kinase inhibitors (TKIs) in addition to platinum-based chemotherapy. This allows targeting several cancer cell populations that may reside within the same tumor. Using numerous treatments simultaneously can reduce tumor growth and postpone the development of medication resistance.
-
You could also keep taking TKI after the progression is over. When an illness worsens, treatment is often discontinued. But discontinuing the drug can make some lung tumors with EGFR mutations develop very quickly. In a lot of cases, targeted therapy is still performed while radiation or surgery is used to treat some parts of the tumor. The ASPIRATION clinical trial showed that continuing Erlotinib after the disease worsened helped some people prevent it from worsening further.
3. Advance Diagnostics
This includes liquid biopsy and genomic profiling
- Liquid Biopsy:
-
A liquid biopsy is a non-invasive procedure that detects circulating tumor DNA in a patient's blood. This procedure enables clinicians to track genetic alterations in the tumor without doing a typical tissue biopsy. Liquid biopsy also allows for frequent monitoring during therapy, which helps to follow tumor development and improve personalized cancer care.
-
Doctors can detect new mutations that confer resistance to targeted medicines by analyzing circulating tumor DNA. Detecting these mutations early on allows doctors to change the treatment approach, such as switching to a different targeted medicine.
-
-
Genomic Profiling: It is a test that examines the genes in a tumour to identify specific changes or mutations. These changes can help doctors understand how the cancer is growing and which treatments might work best.
Conclusion:
For NSCLC to be treated, resistance to targeted medicines must be overcome. Although specific drugs can work very well, cancer cells can evolve over time, making the treatment ineffective. Combination therapy, new drugs, and techniques like liquid biopsy help doctors find resistance early on and change treatment plans as needed. Find out how to address resistance and improve treatment outcomes by talking to our cancer specialist.
Key Takeaways
-
In non-small cell lung cancer (NSCLC), resistance to targeted therapy arises when cancer cells adapt and stop responding to treatment.
-
Tumour characteristics, activation of the alternative pathway, or genetic mutations could be the cause.
-
More recent drugs, such as next-generation ALK inhibitors, can help overcome resistance and improve outcomes.
-
Combination therapy, as well as continued treatment with local therapies, can help to delay resistance and decrease tumor progression.
-
Liquid biopsies aid early detection of resistance, enabling rapid therapeutic adjustments.
